ArticleInternational journal of surgery (London, England)2026
Patient-specific 3D-bioprinted anti-fibrosis barriers to reduce adhesions after abdominal and pelvic surgery.
Article in International journal of surgery (London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Adhesions after surgery continue to pose serious issues. Postoperatively, adhesions are one of the most common causes of chronic abdominal pain, infertility, intestinal blockage, and healthcare-related financial burden. Only a few anti-adhesion products have been developed to prevent these problems and most of them show suboptimal outcomes due to a lack of conformity to the location of the surgery, poor durability, and low bioactivity. In this letter, we discuss the need for new solutions, and present a new concept: Customized, 3D-printed barriers (Bio-Printed Anti-Fibrosis Barriers) made from regenerative biomaterials. Custom-designed biomaterials can fit precisely into the surgical cavity, provide focused delivery of anti-inflammatory agents, and guide the regeneration of tissue. The convergence of bioprinting technology and regenerative biomaterials may serve as an innovative avenue for decreasing morbidity associated with adhesions after oncologic and reconstructive surgery.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.